Propanc's PRP Increases Chemotherapy Sensitivity in Pancreatic Cancer Cells in Preclinical Study

Propanc Biopharma reported preclinical findings showing PRP pretreatment increased chemotherapy responsiveness in chemotherapy-resistant pancreatic cancer cells. Sequential PRP treatment followed by chemotherapy produced the study’s strongest functional response. PRP alone reduced proliferation by 54% in resistant cells; invasive capacity fell 47%. Combining PRP with a TGF-β inhibitor achieved 80% invasion inhibition in resistant cells. A Phase 1b first-in-human trial in advanced solid tumors is planned for Q1 2027; patient benefit remains unproven. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via (Ref. ID: 202610160836PRIMZONEFULLFEED9847369) on October 16, 2026, and is solely responsible for the information contained therein. (C)